Zhongxin Jingwei, February 23 -- According to the China Enforcement Information Disclosure Network, Ningxia Zhongke Biotechnology Co., Ltd. (hereinafter referred to as "Ningke Biotechnology") has recently added 4 pieces of information on the person subject to execution, and the execution targets are respectively, totaling more than 1100 million, and the enforcement courts are all Yinchuan Xingqing District People's Court.
*: China Enforcement Information Disclosure Network.
According to the information on the official website, Ningke Biotech was founded in 1958 and listed on the Shanghai ** Stock Exchange in May 1998. The company is committed to optimizing the asset structure, actively deploying mergers and acquisitions in the capital market, and actively exploring diversified development.
In terms of performance, Ningke Biotech expects to achieve a net profit attributable to shareholders of listed companies of about -500 million yuan to -350 million yuan in 2023. The company's net profit attributable to shareholders of listed companies in 2022 was -14148430,000 yuan.
Talking about the main reason for the pre-loss of performance, Ningke Biotechnology said that the company's holding subsidiary, Ningxia Zhongke Biotech New Materials, had insufficient liquidity, failed to fully release production capacity, and significantly reduced gross profit; The impairment loss of inventory and fixed assets was about 1400 million yuan; The provision of interest on non-related party borrowings resulted in an increase in financial expenses. (Zhongxin Jingwei app).
For more exciting content, please pay attention to the official WeChat of JWVIEW***